ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
Status:
Not yet recruiting
Trial end date:
2028-02-01
Target enrollment:
Participant gender:
Summary
This is a phase 1b study of P30-linked EphA2, CMV pp65, and survivin vaccination
(collectively called the P30-EPS vaccine) in HLA-A*0201 positive patients with a newly
diagnosed, unmethylated, and untreated World Health Organization (WHO) grade IV malignant
glioma.